Lactobacillus rhamnosus GG Regulates Host IFN-I Through the RIG-I Signalling Pathway to Inhibit Herpes Simplex Virus Type 2 Infection.

Publisher: Springer Country of Publication: United States NLM ID: 101484100 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1867-1314 (Electronic) Linking ISSN: 18671306 NLM ISO Abbreviation: Probiotics Antimicrob Proteins Subsets: MEDLINE

Original Publication: New York, NY. : Springer

Lacticaseibacillus rhamnosus*/physiology ; Herpesvirus 2, Human*/physiology ; Herpesvirus 2, Human*/immunology ; Signal Transduction* ; Interferon Type I*/metabolism ; Interferon Type I*/immunology; Animals ; Mice ; DEAD Box Protein 58/metabolism ; DEAD Box Protein 58/genetics ; Herpes Simplex/immunology ; Humans ; Mice, Inbred C57BL ; Female ; Probiotics/pharmacology

Numerous recent studies have demonstrated that the commensal microbiota plays an important role in host immunity against infections. During the infection process, viruses can exhibit substantial and close interactions with the commensal microbiota. However, the associated mechanism remains largely unknown. Therefore, in this study, we explored the specific mechanisms by which the commensal microbiota modulates host immunity against viral infections. We found that the expression levels of type I interferon (IFN-I) and antiviral priming were significantly downregulated following the depletion of the commensal microbiota due to treatment with broad-spectrum antibiotics (ABX). In addition, we confirmed a unique molecular mechanism underlying the induction of IFN-I mediated by the commensal microbiota. In vivo and in vitro experiments confirmed that Lactobacillus rhamnosus GG (LGG) can suppress herpes simplex virus type 2 (HSV-2) infection by inducing IFN-I expression via the retinoic acid-inducible gene-I (RIG-I) signalling pathway. Therefore, the commensal microbiota-induced production of IFN-I provides a potential therapeutic approach to combat viral infections. Altogether, understanding the complexity and the molecular aspects linking the commensal microbiota to health will help provide the basis for novel therapies already being developed.
Competing Interests: Declarations Ethical Approval and Consent to Participate All the research involving animal were approved by the Medical Ethics Committee of Southern Medical University (Approval protocol no. SMUL2021045). Consent for Publication Not applicable. Competing Interests The authors declare no competing interests.
(© 2023. The Author(s).)

Trends Immunol. 2017 Aug;38(8):542-557. (PMID: 28579323)
Cell Rep. 2019 Jul 2;28(1):245-256.e4. (PMID: 31269444)
Immunity. 2022 May 10;55(5):847-861.e10. (PMID: 35545033)
Nutrients. 2017 Oct 23;9(10):. (PMID: 29065562)
Immunity. 2012 Feb 24;36(2):166-74. (PMID: 22365663)
J Virol. 2013 Feb;87(3):1443-53. (PMID: 23152529)
Bull World Health Organ. 2020 May 01;98(5):315-329. (PMID: 32514197)
Adv Immunol. 2011;109:87-124. (PMID: 21569913)
PLoS Pathog. 2019 Oct 11;15(10):e1008072. (PMID: 31603951)
Sex Transm Infect. 2004 Aug;80(4):272-6. (PMID: 15295123)
Cell Host Microbe. 2017 Apr 12;21(4):421-432. (PMID: 28407480)
Antiviral Res. 2012 Mar;93(3):340-5. (PMID: 22269645)
Immunity. 2011 May 27;34(5):680-92. (PMID: 21616437)
Lancet. 2007 Dec 22;370(9605):2127-37. (PMID: 18156035)
Med Microbiol Immunol. 2015 Apr;204(2):161-76. (PMID: 25209142)
Nat Immunol. 2012 Feb 16;13(3):214-22. (PMID: 22344284)
Immunology. 2011 Apr;132(4):466-74. (PMID: 21320124)
Folia Microbiol (Praha). 2020 Jun;65(3):439-449. (PMID: 32072398)
Appl Microbiol Biotechnol. 2022 Dec;106(24):8233-8243. (PMID: 36385568)
J Extracell Vesicles. 2022 Apr;11(4):e12187. (PMID: 35430766)
J Biol Chem. 2017 May 5;292(18):7285-7294. (PMID: 28289098)
Ann N Y Acad Sci. 2008 Nov;1143:1-20. (PMID: 19076341)
Cell Host Microbe. 2017 Jul 12;22(1):13-24.e4. (PMID: 28669672)
Immunity. 2013 May 23;38(5):855-69. (PMID: 23706667)
Future Oncol. 2010 Aug;6(8):1289-311. (PMID: 20799875)
Front Med (Lausanne). 2018 Jun 13;5:181. (PMID: 29951482)
J Virol. 2009 Nov;83(21):11196-200. (PMID: 19692470)
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):238-44. (PMID: 21860356)
Nat Rev Microbiol. 2017 May;15(5):259-270. (PMID: 28316330)
J Immunol. 2000 Apr 15;164(8):4220-8. (PMID: 10754318)
Annu Rev Virol. 2019 Sep 29;6(1):567-584. (PMID: 31283436)
Nat Rev Immunol. 2015 Feb;15(2):87-103. (PMID: 25614319)
Nat Rev Immunol. 2014 Jan;14(1):36-49. (PMID: 24362405)
Folia Microbiol (Praha). 2017 Mar;62(2):151-156. (PMID: 27858281)
Gut Microbes. 2022 Jan-Dec;14(1):2018900. (PMID: 34965194)
Science. 2017 Aug 4;357(6350):498-502. (PMID: 28774928)
Immunity. 2006 Sep;25(3):373-81. (PMID: 16979569)
Anaerobe. 2011 Dec;17(6):334-6. (PMID: 21621625)
Biomed Pharmacother. 2016 Oct;83:536-541. (PMID: 27447122)
Microbes Infect. 2000 Apr;2(5):543-6. (PMID: 10865199)
J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41. (PMID: 30741841)
Front Cell Infect Microbiol. 2019 Apr 30;9:127. (PMID: 31114761)
Isr Med Assoc J. 2003 Nov;5(11):767-9. (PMID: 14650098)
Infect Genet Evol. 2011 Aug;11(6):1239-42. (PMID: 21524717)
Cell. 2020 Nov 25;183(5):1312-1324.e10. (PMID: 33212011)
Annu Rev Microbiol. 2012;66:177-96. (PMID: 22994491)
Front Cell Infect Microbiol. 2012 Aug 09;2:104. (PMID: 22919693)
J Med Genet. 2022 Mar;59(3):294-304. (PMID: 33495304)
Curr Opin Immunol. 2013 Aug;25(4):450-5. (PMID: 23830047)
Nat Rev Immunol. 2020 Sep;20(9):537-551. (PMID: 32203325)
Front Microbiol. 2018 Jul 02;9:1451. (PMID: 30034377)

2021A1515110578 Basic and Applied Basic Research Foundation of Guangdong Province; 202201011480 Guangzhou Science and Technology Plan Project-Basic and Applied Basic Research Foundation; 2019M662990 China Postdoctoral Science Foundation; 82025024 National Science Fund for Distinguished Young Scholars

Keywords: Lactobacillus rhamnosus GG; Commensal microbiota; Herpes simplex virus type 2; Interferon type I; RIG-I

0 (Interferon Type I)
EC 3.6.4.13 (DEAD Box Protein 58)

Date Created: 20230825 Date Completed: 20241118 Latest Revision: 20241121

20241121

PMC11573810

10.1007/s12602-023-10137-8

37624569